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Abstract
Natriuretic peptides play an important role in water and salt homeostasis and in the regulation of the cardiovascular system. In recent
years, exogenous administration of natriuretic peptides has primarily been used to improve our understanding of the role of natriuretic
peptides. Also, it became evident that natriuretic peptides may be used therapeutically. Because of their peptide character, they cannot be
administered orally and, therefore, may be used for short-term intravenous therapy only. In recent years, inhibitors of neutral
endopeptidase, which degrades natriuretic peptides to inactive metabolites, have been investigated. This review focuses on the potential
benefits of increasing natriuretic peptide levels, either through exogenous administration or inhibiting the degradation of endogenous
natriuretic peptides. Ó 2001 Elsevier Science B.V. All rights reserved.
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1. Rationale for the therapeutic increase in natriuretic development of arteriosclerosis, hypertension and progres-
peptides levels sion of congestive heart failure (CHF) [7–9].
Natriuretic peptides are importantly involved in water 1.1. Natriuretic peptides in various cardiovascular
and sodium balance and cardiovascular homeostasis (Fig. diseases
1). In response to an increase in filling pressures and
stretch of the atrial and ventricular walls, atrial natriuretic The pivotal role of natriuretic peptides in the early
peptide (ANP) and brain or B-type natriuretic peptide development of CHF has been demonstrated in various
(BNP) are released into the bloodstream [1,2]. In addition, animal studies. Prevention of the early rise of ANP in
several neurohormones such as endothelin-1 (ET-1), ar- pacing-induced CHF by surgical removal of the atrial
ginine vasopressin (AVP), and catecholamines stimulate auricles may result in hemodynamic deterioration and in
the secretion of natriuretic peptides [3,4]. This leads significant activation of the renin–angiotensin system [10].
primarily to a reduction in preload by increasing water and In contrast to ANP, BNP is not or only minimally elevated
sodium excretion, but also by shifting plasma from the in acute pacing-induced CHF [11]. Administration of BNP
intravascular to the extravascular space [5]. The effects of resulted in haemodynamic improvement and prevention of
ANP and BNP are mediated by the transmembrane water and sodium retention [11], a finding we recently
guanylyl-cyclase receptor type A, which promotes intracel- could confirm (unpublished data). However, further in-
lular cGMP formation. Thus, they cause arterial and crease in already elevated serum ANP levels in this setting
venous vasodilation [6]. Additional important properties was without effect (unpublished data, Fig. 2). In patients
include the ability to inhibit the activity of various suffering from large myocardial infarction the rise in
neurohumoral systems, involved in the pathogenesis and BNP-levels results in left ventricular systolic dysfunction,
which is seen as a compensatory mechanism to prevent
further deterioration [12]. In chronic CHF, natriuretic
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models. Transgenic mice overexpressing ANP or BNP
were shown to have lower blood pressure than control
animals [16,17]. Disruption of the pro-ANP gene in mice
elevated blood pressure, particularly in the presence of
salt-rich diet [18]. Salt-resistant hypertension was observed
in mice lacking the guanylyl cyclase type A receptor [19].
Further, ANP may play a role in counteracting excess of
mineralocorticoids [20].
1.2. Effects of natriuretic peptides on other
neurohormones and mitogenesis
In addition to the well-described inhibitory effect on
renin release [21], natriuretic peptides may also counteract
other vasoconstrictor neurohumoral systems. Among
others, natriuretic peptides may inhibit ET-1 secretion inFig. 1. Effects of natriuretic peptides released from the heart as a result
vitro [8]. Moreover, there is general agreement that ANPof increased cardiac wall stretch (increased venous return) or various
neurohormones. Both peripheral and central effects lead to reduction of inhibits sympathetic activity [9,22,23], despite some con-
the initial promoters. ? denotes effects or mechanisms not yet completely tradictory findings [24]. Effects of BNP in this context are
elucidated. ANP, atrial natriuretic peptide; AVP, arginine vasopressin; less well known. We have recently found inhibition ofBNP, brain natriuretic peptide; ET-1, endothelin-1; SNS, sympathetic
systemic and regional sympathetic activity by exogenousnervous system.
BNP in both healthy controls and CHF patients [25],
pointing to a potential role of natriuretic peptides in thepeptides may contribute to maintenance of cardiac function
regulation of the sympathetic nervous system.in early, asymptomatic stages of disease. At a later stage,
Moreover, natriuretic peptides have antimitogenic activi-however, progression of CHF may be related to loss of
ty. ANP and C-type natriuretic peptide (CNP) have beenefficacy of natriuretic peptides [13].
shown to inhibit mitogenesis in cultured vascular smoothNatriuretic peptides may also play a role in arterial
muscle cells and in balloon injured carotid arteries [26,27].hypertension. Polymorphism of the ANP gene was found
These effects seem to be cGMP-mediated, implying thatin some patients with essential hypertension [14]. More-
natriuretic peptides may modulate growth in the vesselover, a lower ratio of the guanylyl-cyclase type A receptor
wall and possess inhibitory properties on the developmentto the clearance receptor was found in obesity-related
of arteriosclerosis [28]. ANP further inhibits growth ofhypertension [15]. Other evidence derives from animal
cardiac fibroblasts in vitro, independently of the underlying
mechanism of stimulated proliferation [29,30]. Therefore,
natriuretic peptides may favourably affect remodelling by
reducing the myocardial proliferative response to injury.
2. Effects of systemic and local administration of
natriuretic peptides
The hemodynamic effects of natriuretic peptides have
been widely investigated in both health and cardiovascular
disease. Whereas reduction in cardiac filling pressures has
been almost uniformly reported, arterial vasodilatation as a
response to natriuretic peptides is less consistent. In theory,
one would expect reduction in systemic vascular resist-
ance. Some studies showed an increase in cardiac output
despite significant reduction in filling pressures [31–33].Fig. 2. Hemodynamic effects of equimolar doses of ANP and BNP (10
Others have reported no effect on or even an increase inpmol /kg per min) in a crossover comparison in acute pacing-induced
heart failure (AHF) in eight dogs (mean6S.E.M.). Tachycardic pacing systemic vascular resistance [34–36]. The latter finding
was applied for 1 h to increase pulmonary wedge pressure (PCWP) to 15 might be explained by a counterregulatory activation of
mmHg before ANP and BNP was given for 30 min each in random order. baroreceptors with high doses of natriuretic peptides [28],
Between infusions, there was a washout period of 30 min. *All differ- despite their inhibitory effect on the sympathetic nervous
ences between ANP and BNP P,0.01 (Wilcoxon Exact Test). CO,
system and the lowering of the activation threshold ofcardiac output; SVR, systemic vascular resistance; RAP, right atrial
pressure. vagal afferents [37].
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The arterial response to exogenous natriuretic peptides 2.2. Administration of natriuretic peptides in coronary
may vary regionally. Natriuretic peptides cause vasodilat- artery disease
ation in renal afferent arterioles but vasoconstriction in
efferent arterioles [38], increasing the glomerular hydro- Natriuretic peptides have effects that are of potential
static pressure, and thereby enhancing glomerular filtration benefit in coronary artery disease. Thus, infusion of ANP
rate. In healthy conscious dogs, natriuretic peptides have reduced the extent and severity of myocardial perfusion
been shown to cause mesenteric vasoconstriction, but defects and prevented ST-segment depression during exer-
different responses have been observed in other vascular cise [42]. Both ANP and BNP infused into the left main
beds in the same animals. Interestingly, the vascular coronary artery increase coronary sinus blood flow and
response was independent of the autonomic nervous decrease coronary vascular resistance [54,55]. Natriuretic
system [39,40]. Thus, natriuretic peptides seem to be peptides may reduce chest pain and ECG changes in
involved in the distribution of regional blood flow. Al- patients with vasospastic angina [56]. It has been sug-
though the underlying mechanism for the vasoconstrictive gested that ANP improves myocardial perfusion to areas of
effect of natriuretic peptides is still unexplained, it may be ischaemia by acting on collateral vessels [57]. Pacing-
hypothesised that the arterial response to natriuretic pep- induced myocardial ischaemia has been attenuated in
tides is not uniform and depends on the underlying patients with coronary stenosis with but not in patients
conditions. So far, systemic vasodilatation has primarily without collaterals [58]. Natriuretic peptides may therefore
been observed in patients with manifest cardiovascular or contribute to the local homeostatic regulation during
renal disorders [31–33,36]. conditions of myocardial ischaemia, similarly to the local
Because of the prevailing beneficial effects, there was distribution of blood discussed earlier [39].
early interest in the therapeutic use of ANP in humans There may be additional effects that are beneficial in the
[41]. Other atrial natriuretic peptides, such as urodilatin acute coronary syndrome. Neutrophils incubated in either
(i.e. proANP(95-126)) and vessel dilator (i.e. proANP(31- ANP or BNP showed less adhesion and elastase release,
67)), and BNP received attention. Administration of nat- and reduced detachment of endothelial cells [59]. Neutro-
riuretic peptides has been investigated in patients with phils are believed to contribute to endothelial cell damage
various cardiovascular conditions such as arterial hyperten- in ischemic and reperfusion injury. They contain neutral
sion [21], myocardial infarction, coronary artery disease endopeptidase, which is significantly increased in acute
[42,43], and CHF [44]. Moreover, therapeutic use of myocardial infarction [60]. Thus, deficient inhibition of
natriuretic peptides was considered in other conditions, neutrophils by natriuretic peptides in acute coronary
such as renal insufficiency [45,46], liver cirrhosis [47,48], syndrome may play an essential pathophysiological role.
bronchial obstruction [49,50], and in the immediate post- This may be seen in line with the relationship of elevated
operative period after cardiac surgery [51]. white blood cell counts to reduced myocardial perfusion
and high incidence of new CHF in acute myocardial
infarction [61]. Infusion of natriuretic peptides may there-
2.1. Administration of natriuretic peptides in arterial fore prove to be useful in patients with acute coronary
hypertension syndromes.
In arterial hypertension, ANP has been shown to sig- 2.3. Administration of natriuretic peptides in congestive
nificantly reduce blood pressure in a dose-dependent heart failure
manner [21,36]. In addition to increasing sodium and water
excretion, which may be enhanced compared to healthy Several studies investigated the effects of natriuretic
controls [52], natriuretic peptides may significantly reduce peptides on haemodynamics, renal function, and other
the activity of the renin–angiotensin–aldosterone system circulating neurohormones in CHF. The majority of the
[21]. Moreover, infusion of BNP was found to improve human studies were conducted in patients with advanced
diastolic function of the left ventricle in patients with CHF. Initial results were promising as they showed a
isolated diastolic CHF due to hypertensive heart disease significant reduction in filling pressures and systemic
[53]. These effects are desirable and may be more favour- vascular resistance with an increase in cardiac output [62].
able than those of other antihypertensive drugs, some of Sodium and water excretion were increased and both
which may stimulate vasoconstrictor neurohumoral sys- circulating noradrenaline and aldosterone decreased com-
tems. However, lack of an oral form imposes limitations. pared to placebo [44]. The expectations were slowed down
Acute decompensation of pure diastolic CHF may be an when it became evident that the efficacy of natriuretic
exception to this notion [53]. Nevertheless, these studies peptides may be lost over time as CHF progresses [63,64].
expand the current pathophysiological understanding of This phenomenon seems to correlate with the transition
arterial hypertension and set the stage for the use of drugs, from asymptomatic to overt CHF [13]. In the human
which aim to increase the endogenous levels of natriuretic forearm model, both intra-arterial ANP and BNP caused
peptides (i.e. neutral endopeptidase inhibitors, see below). less vasodilatation and local production of cGMP in
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patients with CHF than in healthy volunteers [63]. The
production of cGMP in relationship to the extraction of
ANP across the lung [65] and the leg [64] was significantly
reduced in advanced compared to early CHF. One of the
underlying factors for this observation may be downregula-
tion of the guanylyl-cyclase type A receptor although this
has not yet been specifically investigated in CHF. Dow-
nregulation of this receptor was found in patients with
chronically elevated levels of natriuretic peptides in
chronic but not in paroxysmal atrial fibrillation [66].
However, natriuretic peptides in CHF were not found in all
studies [67]. Moreover, hyporesponsiveness may differ
between various types of natriuretic peptides [68]. A recent
study showed that vessel dilator strongly enhanced sodium
Fig. 3. Hemodynamic effects of two doses of nesiritide (human BNP,
and water excretion and had beneficial hemodynamic
mg/kg per min) versus placebo in acute decompensated heart failure in
effects in patients with CHF [69]. In contrast, another 127 patients randomly assigned to one treatment group. Changes from
fragment of pro-ANP (i.e. proANP(1-30) had significantly baseline after 6 h of BNP infusion (mean6S.D.). Comparisons among all
three groups P#0.001 by the omnibus F-test (one-way ANOVA); *P,less diuretic and natriuretic effects in CHF compared to
0.001 for the pairwise comparison with placebo by the F-test. PCWP,healthy controls. This reduced efficacy was significantly
pulmonary capillary wedge pressure; SBP, systolic blood pressure; SVR,different to the effects of vessel dilator [68].
systemic vascular resistance. Adapted from Colucci et al. [32].
Although not based on scientific grounds, it was post-
ulated that hyporesponsiveness is also less pronounced for
BNP than for ANP [70]. Intravenous administration of respectively, P50.03). After 6 h, dyspnoea was improved
BNP caused a dose-dependent reduction in filling pressures in 56 and 50% of the patients receiving low and high dose
and peripheral vascular resistance and an increase in nesiritide, respectively, but in only 12% of the patients
cardiac output in patients with acutely decompensated receiving placebo (P,0.001). A similar reduction in
CHF [70]. Most recently, the beneficial hemodynamic fatigue (32 and 38%, respectively, vs. 5%, P,0.001) and
effects of BNP (nesiritide, i.e. recombinant human BNP) in improvement in clinical status (Fig. 4) were observed. In a
symptomatic CHF were confirmed in two large studies second comparative arm, the two doses of nesiritide (0.015
[31,32]. mg/kg per min, n5103; 0.03 mg/kg per min, n5100)
The first of these studies investigated the hemodynamic were compared with standard therapy (n5102; most
effects of three different doses of nesiritide (0.015, 0.03, commonly dobutamine) for up to 7 days to detect changes
and 0.06 mg/kg per min) over 24 h compared to placebo in in symptoms and to evaluate safety. There were similar
103 patients with decompensated CHF [31]. Patients had a improvements in symptoms in all three treatment groups.
pulmonary capillary wedge pressure $18 mmHg and a Although the patients lost similar amounts of weight,
2
cardiac index #2.7 l /min per m . Nesiritide had beneficial intravenous diuretics were less often needed in patients
dose-dependent hemodynamic effects. The drug was gen- assigned to nesiritide (84 and 75%, respectively) than in
erally well tolerated, but hypotension occurred more often patients under standard treatment (96%, P,0.001). The
with high doses of BNP (P50.027 trend test). Unexpected-
ly, there were no significant effects on sodium or water
excretion. This may be in contrast to the renal effects
observed with vessel dilator [69], although no direct
comparison of these two agents in CHF has been pub-
lished. Hemodynamic peak effects of nesiritide were seen
3 h after the start of infusion and persisted to the end of the
infusion (24 h). No rebound effect was observed after
cessation of the infusion.
The largest trial investigating the therapeutic use of BNP
in CHF has been published most recently [32]. In a first
arm with 127 patients, efficacy of 0.015 and 0.03 mg/kg
per min of nesiritide over 6 h was compared to placebo.
The results showed beneficial hemodynamic changes (Fig.
Fig. 4. Effects on overall symptoms of two doses of nesiritide (human3), increased urine production (mean urine output over 6 h:
BNP, mg/kg per min) versus placebo in acute decompensated heart failureplacebo vs. low dose vs. high dose nesiritide 380, 560 and (n5127). Symptoms were assessed on a five-category scale. Comparison
659 ml, respectively, P50.004), and reduction in plasma among the three groups, P,0.001 by non-parametric ANOVA. Adapted
aldosterone concentration (117, 269, and 244 pmol / l, from Colucci et al. [32].
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most common side effect of nesiritide was dose-related, 2.5. Administration of natriuretic peptides in other
mostly asymptomatic hypotension (12 and 24%, respec- conditions
tively, vs. 7%, P,0.01). Bradycardia was more common
in the nesiritide groups (4 and 5%, respectively, vs. 0%, Similarly controversial conclusions were drawn in pa-
P,0.05) and nonsustained ventricular tachycardia was tients with liver cirrhosis. Both a blunted and a preserved
noted less in the high dose nesiritide group (1%) than in response to natriuretic peptides have been found in ad-
the other two groups (low dose nesiritide 10%, standard vanced liver disease [47,48,80,81]. In theory, the renal
therapy 8%, P,0.05). effects of natriuretic peptides, if preserved, may help to
These trials underline the potential benefit of nesiritide reduce the pressure in the portal vein. Furthermore,
in decompensated CHF. Standard therapy in this setting although natriuretic peptides do not seem to have direct
still requires intravenous diuretics, dobutamine, milrinone, effects on hepatic vascular conductance [40], the reduction
nitroglycerin, and sodium nitroprusside. All these therapies in mesenteric blood flow may further contribute to a
have significant drawbacks, including arrhythmias reduced portal venous pressure [39]. This is in line with
(dobutamine, milrinone [71], potentially augmented by other experimental data, which show that natriuretic pep-
electrolyte disturbances due to diuretics [72]), development tides may reduce portal venous pressure despite loss of
of tolerance (nitroglycerin [73]), toxic effects (sodium renal effects in cirrhotic rats [81]. It remains to be seen
nitroprusside), and stimulation of vasoconstrictor neuro- whether this is of therapeutic significance in humans with
humoral systems (pure vasodilators). Hypotension as the portal hypertension.
most common side effect of nesiritide might be overcome In patients with bronchoconstriction, local (i.e. inhaled)
by careful uptitration, which so far has not been tested. and systemic application of natriuretic peptides consistent-
ly caused bronchodilation [49,50,82]. The combined use of
a locally applied substance increasing cAMP (b2-stimula-
2.4. Administration of natriuretic peptides in acute renal tion) with systemic urodilatin, which increases cGMP, was
failure significantly more effective than either therapy alone [50].
In addition, ANP may act as a bronchoprotective agent
In experimental and small human studies, atrial nat- after allergic reactions [83]. Currently, there are insuffi-
riuretic peptides showed beneficial effects in acute renal cient data available about the long-term effects of nat-
failure [74,75]. ANP was also investigated in an open- riuretic peptides in such patients with bronchoconstriction.
label, clinical study in 53 patients with acute tubular Seemingly, rather high doses are needed to obtain signifi-
necrosis, transiently increasing creatinine clearance during cant effects with locally applied ANP [84]. Thus, cost-
infusion and decreasing the need for dialysis [45]. In effectiveness may prevent natriuretic peptides from being
contrast, a randomised double-blinded trial failed to show used as a therapeutic agent for bronchoconstriction.
anatritide, a synthetic 25-amino-acid form of ANP, to Natriuretic peptides have also been investigated during
ameliorate dialysis-free survival in 504 critically ill pa- cardiac surgery [51,85,86]. A low ANP dose had favour-
tients with acute tubular necrosis [46]. Nevertheless, in a able effects given during and for the first 24 h after
predefined subgroup of patients with oliguria (i.e. ,400 ml coronary bypass grafting, improving hemodynamics and
urine /day), a 24-h infusion of anatritide improved dialysis- respiratory index and reducing neurohumoral stimulation,
free survival to 27% compared to 8% in the placebo use of diuretics, and pleural effusions [51]. Similarly, ANP
treated group (P50.008). However, anatritide was detri- improved hemodynamics and augmented urinary excretion
mental in the non-oliguric patient population (48 vs. 59% given on the first postoperative day after open-heart
dialysis-free survival, P50.03). Whether underlying surgery [85]. The same was found in patients undergoing
pathophysiological conditions and/or the type of nat- Fontan operation [86]. Therefore, administration of nat-
riuretic peptide may be important in this regard needs to be riuretic peptides during the perioperative period may be
tested. A recent study in rats with established ischemic beneficial and may deserve further investigation.
non-oliguric acute renal failure found marked improvement
in survival by vessel dilator [76]. In contrast, urodilatin did
not reduce the incidence of renal replacement therapy in 3. Increasing endogenous levels of natriuretic
critically ill patients suffering form oliguric acute renal peptides
failure [77]. Additionally, urodilatin did not improve renal
function in patients with acute renal failure after major Long-term increase in natriuretic peptides may be a
abdominal surgery [78], but was effective in acute renal desirable therapeutic target. So far, the only means to
failure after cardiac surgery [74,79]. So far, the results of achieve this goal is to reduce the degradation of natriuretic
studies with natriuretic peptides in acute renal failure are peptides by neutral endopeptidase inhibition [87]. Selective
controversial and at this time, there is no clear evidence to neutral endopeptidase inhibition increases the levels of
support a therapeutic role in this setting. natriuretic peptides, resulting ultimately in increased excre-
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tion of sodium, water, ANP, and cGMP without altering pressure in 71% of patients with mild hypertension [103].
urinary potassium excretion [88]. However, neutral endo- The high response rate may relate to the fact that omapat-
peptidase inhibition has demonstrated only a limited ability rilat may be effective independently of the renin levels.
to lower systemic blood pressure [89], which may be Thus in patients with salt-sensitive low renin hypertension,
related to vasoconstrictive properties of selective neutral as often observed in black individuals, ACE inhibitors
endopeptidase inhibition [90]. In addition to the vasocon- usually are not as effective as in patients with normal or
strictive potential of natriuretic peptides [39], other mecha- high renin levels [104]. In these patients, inhibition of
nisms may be accountable for these findings. Neutral neutral endopeptidase may be important as it enhances the
endopeptidase is involved not only in degradation of ET-1 levels of natriuretic peptides and lowers plasma volume.
[91] but possibly also in its formation [92]. Thus, selective Although direct comparisons of omapatrilat with other
inhibition of neutral endopeptidase might cause both an blood pressure lowering agents are scarce, omapatrilat
increase and decrease in endothelin-1. Increased levels of seems to be one of the most efficacious antihypertensive
circulating ET-1 could be demonstrated after administra- drugs yet known.
tion of candoxatril, a selective neutral endopeptidase There are effects of omapatrilat beyond pure blood
inhibitor [89]. Similarly, locally applied candoxatrilat pressure lowering. As elevated neurohumoral stimulation
caused vasoconstriction which could be reverted by a is increasingly recognised as an important factor in the
selective ET receptor antagonist [93]. Importantly, neutral pathophysiology of CHF [105], this is also found to be trueA
endopeptidase is also involved in the degradation of in hypertension [106,107]. Similarly, the recently pub-
angiotensin-II (Ang II). Consequently, inhibition of neutral lished HOPE study could show that ACE inhibition
endopeptidase leads to increased levels of Ang II [94]. favourably affects prognosis in patients with arteriosclero-
Apart from bearing potential vasoconstrictive effects, Ang sis independently of the magnitude of blood pressure
II may antagonise the effects of the natriuretic peptides. It lowering [108]. Because of the additional properties of
down-regulates guanylyl cyclase receptors and up-reg- omapatrilat, one might speculate that long-term effects of
ulates cGMP phosphodiesterases, both of which attenuate this new therapeutic tool might prove even better in
the generation of cGMP [30,95]. Therefore, simultaneous improving prognosis in this patient population.
inhibition of both neutral endopeptidase and angiotensin
converting enzyme (ACE) may be synergistic and a 3.2. Vasopeptidase inhibition in congestive heart failure
promising approach to modulate neurohumoral stimulation
in cardiovascular diseases [88]. In line with this concept, Despite significant advances in the medical therapy of
simultaneous inhibition of both neutral endopeptidase and CHF in recent years, prognosis of these patients remains
ACE in animal experiments exhibited hemodynamic and poor [109,110]. On the one hand, vasoconstrictor neuro-
renal effects that were more than additive compared to humoral systems may overcome the endogenous counter-
those caused by inhibition of either one of these enzymes regulatory mechanisms, resulting in progression of CHF
alone [96–98]. Recently, omapatrilat, a vasopeptidase [111]. On the other hand, sodium and water retention cause
inhibitor that inhibits both neutral endopeptidase and ACE, significant problems in these patients. This may, in turn,
has been developed [99]. Omapatrilat shows equipotent, result in deterioration of CHF and hospitalisation [112].
highly selective competitive inhibition of both enzymes, Standard loop-diuretics increase water and salt excretion,
although the rate constant (K ) is slightly higher for neutral but also increase potassium excretion leading to an ele-i
endopeptidase (8.961.0 nmol / l) than for ACE (6.060.4 vated risk of hypokalemia-induced arrhythmias [113]. In
nmol / l). Therefore, omapatrilat acts primarily as an ACE addition, they also stimulate vasoconstrictor neurohumoral
inhibitor in low dosages while it inhibits both enzymes in systems, in particular the renin–angiotensin system. In
higher dosages. contrast, vasopeptidase inhibitors may overcome this prob-
lem, by increasing water and sodium excretion and reduc-
3.1. Vasopeptidase inhibition in hypertension ing preload without affecting potassium excretion and
without stimulating vasoconstrictor neurohumoral systems
Preclinical studies showed the potential advantages of [88]. In dogs, omapatrilat has been shown to improve
omapatrilat over pure ACE-inhibition in various models of cardiac function in pacing-induced CHF [114]. Further-
hypertension [100,101]. Thus, omapatrilat lowered ele- more, omapatrilat was not only able to improve left
vated blood pressure in conscious rats with high, medium, ventricular geometry compared to captopril, but also to
or low renin hypertension [100]. In comparison with a improve survival in cardiomyopathic hamsters [98]. These
calcium antagonist and an ACE inhibitor, omapatrilat was studies might indicate the superiority of a combined
superior in lowering blood pressure. More recently, the inhibition of neutral endopeptidase and ACE compared to
efficacy of omapatrilat was reported in hypertensive pa- ACE inhibition alone.
tients, where it lowered blood pressure in a dose-dependent Most recently, the IMPRESS trial randomly compared
manner [102]. Furthermore, omapatrilat normalised blood omapatrilat (target dose 40 mg daily) with the ACE
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inhibitor lisinopril (target dose 20 mg) in 573 CHF patients
(ejection fraction#40%) over 24 weeks [115]. Although
there was no difference between the two treatment groups
with respect to the primary endpoint of maximal exercise
capacity, there were fewer cardiovascular serious adverse
events in the omapatrilat group than in the lisinopril group
(7 vs. 12%, P50.04). Furthermore, there was a trend
towards less combined endpoints of death and admission to
hospital for worsening CHF and a significant reduction in
the combined endpoint of death, admission to a hospital or
discontinuation of study treatment due to worsening CHF
(Fig. 5). There was also a trend towards improvements in
symptoms of CHF, particularly in highly symptomatic
patients. Although these data are very promising, one has
to be cautious not to over-interpret them, as this study was
not powered to investigate the prognostic effects of
omapatrilat versus isolated ACE inhibition. Underpowered
studies may lead to false positive results as recently shown
in the ELITE-1 trial [116], which could not be confirmed
in the properly powered ELITE-II study [117].
Another study compared different dosages of omapat-
rilat in patients with CHF, most of them previously treated
with either an ACE inhibitor and/or angiotensin-II re-
ceptor antagonists [118]. There was a dose-dependent
improvement in the clinical CHF status with good overall
tolerability of the drug. Moreover, clinical and hemo-
dynamic improvements were dose-dependent and signifi-
cantly different between the three groups for arterial Fig. 6. Effects of different doses of omapatrilat for 12 weeks on leftpressure and left-ventricular ejection fraction (Fig. 6). ventricular ejection fraction and systolic blood pressure (mean6S.E.M.)
There was also a significant enhancement in water and in humans with left ventricular ejection fraction #40%. Comparisons
among the three groups P,0.01 by one-way ANOVA. Adapted fromsodium excretion and a reduction in blood volume. All
McClean et al. [118].these changes were dose-dependent. The increased cGMP
production as measured by urinary cGMP seemed to be an
important mechanism of the additional effects of omapat-
rilat. Nevertheless, large-scale controlled clinical trials
have to prove the superiority of this concept over isolated 3.3. Tolerability of vasopeptidase inhibition
ACE inhibition (6diuretics) before omapatrilat may be
recommended for the treatment of CHF. Despite the promising data in both arterial hypertension
and CHF, there are important caveats. In both studies
[115,118], only patients with prior ACE inhibitor treatment
were included, with few exceptions. Therefore, it is not
surprising that few ACE-inhibition specific adverse effects
were reported. With this in mind, one has to be cautious
when comparing the tolerability of omapatrilat with ACE
inhibitors [119]. Though rare, a potentially fatal adverse
effect of ACE inhibition is angioedema. The widespread
use of ACE inhibitors may lead to a significant number of
deaths due to angioedema. Inhibition of neutral endo-
peptidase not only increases the levels of endogenous
natriuretic peptides but also of other vasodilators such as a
prostacyclin, adrenomedullin and, more important in this
context, bradykinin [97]. Accumulation of bradykinin is
Fig. 5. Death and comorbid events of worsening heart failure in patients
the most probable cause of angioedema in patients treated
with congestive heart failure after 24 weeks of therapy with either
with ACE inhibitors [120]. Therefore, one may assumeomapatrilat 40 mg daily (n5298) or lisinopril 20 mg daily (n5284).
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